{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:19:08Z","timestamp":1787548748161,"version":"build-2736575974"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective\/background<\/jats:title>\n                    <jats:p>To evaluate the impact of Spatially Fractionated Radiation Therapy (SFRT) on symptomatic relief and survival outcomes in patients with large-volume tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 60 cancer patients who received SFRT between February 2023 and May 2025 were analyzed in this retrospective study. Collected data comprised demographic characteristics, as well as follow-up information on symptomatic response, best overall response, survival duration, and treatment-related adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>By the end of the median follow-up duration of 15.8 months (3.8\u201330.8 months), 91.7% (55\/60) of patients showed symptomatic relief. Follow-up imaging was available for 51 patients, showing tumor regression in 45 cases (6 showed increased volume after treatment). According to RECIST 1.1 criteria, 17 patients achieved Partial response (PR), 32 had Stable disease (SD), and 2 experienced Progressive disease (PD). The Overall response rate (ORR) was 33.3%, and the Disease control rate (DCR) was 96.1%. The median Overall survival (OS) was 7.6 months (95% CI: 4.3-10.9). Univariate analysis identified that a Biologically effective dose at the Vertex (BED-Vertex) \u2265 88 Gy was significantly associated with treatment response (P = 0.020). All adverse events were mild to moderate in severity, no grade 3 or higher toxicities were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SFRT appeared to be effective with limited toxicities for bulky tumors. BED-Vertex is a significant predictor of response in univariate analysis, suggesting that a strategy of safe BED escalation could enhance palliative efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1817351","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:24:27Z","timestamp":1787545467000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["SFRT alleviates symptoms associated with bulky advanced cancer: a retrospective single-center cohort analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Haiqin","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Cong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Central Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.001","article-title":"Spatial oncology: Translating contextual biology to the clinic","volume":"42","author":"Gong","year":"2024","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41568-025-00883-y","article-title":"Epigenetic regulation of T cell exhaustion in cancer","volume":"26","author":"Kang","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00930-x","article-title":"Applications of cell therapy in the treatment of virus-associated cancers","volume":"21","author":"Toner","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.02.009","article-title":"Embracing cancer complexity: Hallmarks of systemic disease","volume":"187","author":"Swanton","year":"2024","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.6270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","article-title":"Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease","volume":"12","author":"Tabrizi","year":"2010","journal-title":"AAPS J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0892-6","article-title":"Systemic dysfunction and plasticity of the immune macroenvironment in cancer models","volume":"26","author":"Allen","year":"2020","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00745-z","article-title":"Compressive stresses in cancer: characterization and implications for tumour progression and treatment","volume":"24","author":"Linke","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2025.101049","article-title":"Spatially fractionated radiotherapy for re-irradiation: feasibility, safety, treatment planning, and outcomes","volume":"56","author":"Burns","year":"2026","journal-title":"Clin Transl Radiat Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1680342","article-title":"Novel volumetric modulated arc therapy approach for lattice radiation therapy for bulky liver tumors","volume":"15","author":"Chung","year":"2025","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1688215","article-title":"Spatially fractionated radiotherapy combined with CapeOX and bevacizumab for postoperative pulmonary metastasis from urachal carcinoma: a case report","volume":"15","author":"Fang","year":"2025","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"413002","DOI":"10.1088\/1361-6463\/ae0e2d","article-title":"Emerging strategies in radiation therapy: promises and challenges of spatial fractionation, ultra-high dose rates, and nanoparticles","volume":"58","author":"Ghaznavi","year":"2025","journal-title":"J Phys D Appl Phys"},{"key":"B16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1186\/s12917-025-05030-1","article-title":"Lattice radiation therapy for canine sinonasal carcinoma: feasibility study of spatially fractionated radiotherapy using volumetric modulated arc therapy","volume":"21","author":"Gualtieri","year":"2025","journal-title":"BMC Vet Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1495216","article-title":"A preliminary study of linear accelerator-based spatially fractionated radiotherapy","volume":"14","author":"Lee","year":"2024","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1697902","article-title":"Case report: Complete pathologic response in advanced melanoma with SFRT and dual checkpoint inhibition","volume":"15","author":"Hobson","year":"2025","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.04.016","article-title":"Reported early clinical outcomes of forward-planned multileaf collimator-based 3-dimensional conformal spatially fractionated radiation therapy technique for large and bulky tumors","volume":"122","author":"Knight","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4274\/balkanmedj.galenos.2025.2025-2-129","article-title":"Effectiveness and safety of lattice radiotherapy in treating large volume tumors: a systematic review and meta-analysis based on single-arm clinical studies","volume":"42","author":"Li","year":"2025","journal-title":"Balkan Med J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1697888","article-title":"Case report: Early experience with hypoxia-targeted SBRT-based partial tumor irradiation in large and bulky tumors","volume":"15","author":"Penagaricano","year":"2025","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172752","article-title":"Diagnosis-related outcome following palliative spatially fractionated radiation therapy (lattice) of large tumors","volume":"17","author":"Studer","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.08.013","article-title":"Grid spatially fractionated radiation therapy for bulky tumors: a large single institution experience","volume":"124","author":"Wang","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1648847","article-title":"Initial experience of spatially fractionated lattice radiation therapy for palliative treatment of pediatric bulky tumors","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1341584","article-title":"Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study)","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13719","article-title":"The promising effects of lattice radiotherapy for large, fungating, or ulcerating breast cancers: a prospective single-center study","volume":"38","author":"Ferini","year":"2024","journal-title":"In Vivo"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.809279","article-title":"A novel radiotherapeutic approach to treat bulky metastases even from cutaneous squamous cell carcinoma: its rationale and a look at the reliability of the linear-quadratic model to explain its radiobiological effects","volume":"12","author":"Ferini","year":"2022","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15968","article-title":"First-ever clinical experience with magnetic resonance-based lattice radiotherapy for treating bulky gynecological tumors","volume":"42","author":"Ferini","year":"2022","journal-title":"Anticancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/53.1.111","article-title":"Influence of tumor size and surgical resection on cell-mediated immunity in mice","volume":"53","author":"Whitney","year":"1974","journal-title":"J Natl Cancer Inst"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1978.27","article-title":"Recovery of immune competence after tumour resection in mice: correlation with loss of suppressor elements","volume":"37","author":"Gasocyne","year":"1978","journal-title":"Br J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040992","article-title":"Hypoxia-driven immune escape in the tumor microenvironment","volume":"9","author":"Vito","year":"2020","journal-title":"Cells"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.006","article-title":"Lactylation in cancer: Current understanding and challenges","volume":"42","author":"Li","year":"2024","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1364627","article-title":"Stereotactic central\/core ablative radiation therapy: results of a phase I study of a novel strategy to treat bulky tumor","volume":"14","author":"Yang","year":"2024","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13014-026-02841-w","article-title":"Preliminary results from a phase II trial of spatially fractionated radiotherapy combined with immunotherapy and anti-angiogenic therapy in patients with bulky solid tumors: early evidence of promising efficacy and favorable safety","volume":"21","author":"Zhou","year":"2026","journal-title":"Radiat Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133290","article-title":"Lattice or oxygen-guided radiotherapy: What if they converge? Possible future directions in the era of immunotherapy","volume":"13","author":"Ferini","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2019.10.004","article-title":"Spatially fractionated radiation therapy: History, present and the future","volume":"20","author":"Yan","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1568959","article-title":"Stereotactic core ablative radiation therapy for small hypoxic tumors: impact of dosimetric approaches and consequent optimization strategy in the context of spatially fractionated radiation therapy","volume":"15","author":"Xu","year":"2025","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ad4192","article-title":"Spatially fractionated radiation therapy: a critical review on current status of clinical and preclinical studies and knowledge gaps","volume":"69","author":"Prezado","year":"2024","journal-title":"Phys Med Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.10.032","article-title":"High dose bystander effects in spatially fractionated radiation therapy","volume":"356","author":"Asur","year":"2015","journal-title":"Cancer Lett"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2024.05.004","article-title":"Bystander effects in spatially fractionated radiation therapy: from molecule to organism to clinical implications","volume":"34","author":"Jenkins","year":"2024","journal-title":"Semin Radiat Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.09.008","article-title":"Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: the safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)","volume":"141","author":"Tao","year":"2020","journal-title":"Eur J Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00681-y","article-title":"Lymphatic vessels in the age of cancer immunotherapy","volume":"24","author":"Karakousi","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2023.09.006","article-title":"The tumor-draining lymph node as a reservoir for systemic immune surveillance","volume":"10","author":"Delclaux","year":"2024","journal-title":"Trends Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133144","article-title":"Rationale for combing stereotactic body radiation therapy with immune checkpoint inhibitors in medically inoperable early-stage non-small cell lung cancer","volume":"14","author":"Chi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010050","article-title":"Shifting the immune-suppressive to predominant immune-stimulatory radiation effects by SBRT-partial tumor irradiation targeting hypoxic segment (SBRT-PATHY)","volume":"13","author":"Tubin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594212","article-title":"Stereotactic body radiotherapy is effective in modifying the tumor genome and tumor immune microenvironment in non-small cell lung cancer or lung metastatic carcinoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/jci162260","article-title":"Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases","volume":"133","author":"Korpics","year":"2023","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.11.028","article-title":"Bimetallic nanoparticles as cascade sensitizing amplifiers for low-dose and robust cancer radio-immunotherapy","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B55","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS(+)\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1334408","article-title":"Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1515\/oncologie-2024-0040","article-title":"Is an immune-oriented use of radiation therapy possible? An increasingly open question under the spotlight of immunotherapy","volume":"26","author":"Zagardo","year":"2024"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-0315","article-title":"Safety and tolerability of low-dose radiation and stereotactic body radiotherapy + sintilimab for treatment-naive stage IV PD-L1+ non-small cell lung cancer patients","volume":"29","author":"Zhou","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12672-024-01360-y","article-title":"Effectiveness of radiotherapy in delaying treatment changes in primary or secondary immunorefractory oligoprogressive patients: preliminary results from a single-center study","volume":"15","author":"Zagardo","year":"2024","journal-title":"Discov Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41698-025-01178-z","article-title":"Minibeam radiation therapy remodels tumor microenvironment and suppresses HIF-1alpha\/VEGFR axis to overcome radioresistance in triple-negative breast cancer","volume":"9","author":"Fang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251387534","article-title":"Molecular mechanisms underlying the abscopal effect induced by radiotherapy and its synergistic translational potential with immunotherapy","volume":"17","author":"Chen","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1515\/oncologie-2025-0435","article-title":"Lattice radiotherapy-induced dramatic regression of bulky metastases challenges radioresistance compared with homogeneous hypofractionation in anorectal mucosal melanoma: a case report","volume":"28","author":"Ferini","year":"2026","journal-title":"Oncologie"},{"key":"B63","doi-asserted-by":"publisher","first-page":"110898","DOI":"10.2139\/ssrn.5084869","article-title":"Stereotactic reirradiation for in-field lung cancer recurrence after stereotactic ablative radiotherapy: a systematic review and meta-analysis","volume":"208","author":"Jang","year":"2025","journal-title":"Radiother Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1817351\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:24:28Z","timestamp":1787545468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1817351\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":63,"alternative-id":["10.3389\/fonc.2026.1817351"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1817351","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1817351"}}